8 – Assembly of Functional Consortia¶

Annotation-guided consortium assembly in BioRemPP is framed as a multi-objective optimization problem operating at the level of KO annotation data. Rather than selecting individual samples in isolation, this module synthesizes all previous analyses into an integrated decision-support framework. Here, we use the KO annotation, toxicological, and regulatory insights obtained in earlier modules to propose candidate consortia that balance compound annotation coverage, annotation completeness, and KO pathway coverage. The ultimate goal is to translate annotation-level results into hypothesis-driven, scenario-aware strategies for assembling candidate consortia, which require experimental validation before deployment.

8.1. Optimizing for Efficiency: The Minimal Coverage Strategy¶

The first objective is to achieve the broadest possible compound co-annotation coverage using the smallest number of samples. To this end, we begin by identifying non-redundant "annotation groups," defined as groups of samples that share identical or highly similar compound co-annotation profiles. We then formulate and solve a set cover problem to determine the minimal set of groups required to cover all compounds within a given chemical class or target list. The result is a parsimonious candidate consortium that can maximize annotation breadth while minimizing redundancy; experimental validation is required to confirm functional capacity.

8.2. Optimizing for Functional Completeness: The Specialist Selection Strategy¶

The second objective is to maximize KO annotation coverage against specific compound targets. For this purpose, we define an "Annotation Completeness Score" that quantifies how fully a sample's KO annotations cover the required KOs for broad chemical classes and for individual high-priority compounds. This score integrates information on KO presence and pathway coverage. By ranking samples based on this metric, we can identify samples with the most complete KO annotation profiles for a given target, supporting hypothesis-driven selection in scenarios where annotation depth is the primary criterion (experimental validation required).

8.3. Optimizing for Process Integrity: The Pathway Completion Strategy¶

The third objective is to ensure that entire multi-step KO annotation patterns for a target pathway can be covered collectively by the candidate consortium. We address this by examining the distribution of all required KOs for a target metabolic pathway across the available samples. Rather than requiring that a single sample carry all pathway KOs, we adopt the principle of annotation complementarity, identifying consortia in which different samples contribute distinct KO subsets for the pathway. The result is a systematic method for assembling candidates that collectively cover all KO annotations for complex pathways — experimental validation is required to confirm whether the corresponding enzymatic steps are functionally active.

8.4. Balancing Trade-offs: Integrating Strategies into Consortium Profiles¶

Finally, we integrate the outcomes of the minimal coverage, annotation completeness, and pathway coverage strategies into coherent candidate consortium profiles. By jointly considering coverage (breadth), annotation completeness (depth), and KO complementarity, we can characterize each candidate consortium in terms of its annotation-level strengths, limitations, and trade-offs. This integrated view allows users to compare alternative candidates according to annotation criteria — such as prioritizing fewer members for simplicity, favoring higher KO annotation depth for targeted compound classes, or emphasizing pathway KO coverage. In this way, the framework provides a flexible, scenario-aware toolbox for annotation-guided hypothesis generation, to be followed by experimental validation.